Hemophilia B Concept

subject area of

• A brief survey of clinicians’ perceptions of parent preferences for involvement in obstetrical and perinatal management decisions in haemophilia  Journal Articles
• A case of non‐resolving hemophilia B Leyden in a 42‐year‐old male (F9 promoter + 13 A>G)  Journal Articles
• A pilot randomized control trial to evaluate the feasibility of an Internet‐based self‐management and transitional care program for youth with haemophilia  Journal Articles
• A preliminary application of a haemophilia value framework to emerging therapies in haemophilia  Journal Articles
• A study of variations in the reported haemophilia B prevalence around the world  Journal Articles
• A systematic review of definitions and reporting of bleeding outcome measures in haemophilia  Journal Articles
• A therapeutic alternative for haemophiliacs with inhibitors  Journal Articles
• Abnormal hemostasis in a knock‐in mouse carrying a variant of factor IX with impaired binding to collagen type IV  Journal Articles
• An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice  Conferences
• An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.  Journal Articles
• Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B  Journal Articles
• Cardiac surgery in patients with haemophilia B: a case report and review of the literature  Journal Articles
• Cardiovascular disease (CVD) in Canadians with haemophilia: Age‐Related CVD in Haemophilia Epidemiological Research (ARCHER study)  Journal Articles
• Cardiovascular disease prevalence and relevance in haemophilia: a scoping review  Journal Articles
• Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B  Journal Articles
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Journal Articles
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Journal Articles
• Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B  Journal Articles
• Comparing bleed frequency and factor concentrate use between haemophilia A and B patients  Journal Articles
• Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders  Journal Articles
• Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): a prospective, multicentre, open-label, randomised, phase 3a trial.  Journal Articles
• Continuous Infusion of Factor Concentrates: Review of Use in Hemophilia A and Demonstration of Safety and Efficacy in Hemophilia B  Conferences
• Continuous intravenous infusion of a plasma‐derived factor IX concentrate (Mononine^®) in haemophilia B  Journal Articles
• Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption  Journal Articles
• Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project  Journal Articles
• Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B  Journal Articles
• Developing a two‐sided intervention to facilitate shared decision‐making in haemophilia: decision boxes for clinicians and patient decision aids for patients  Journal Articles
• Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia: a discrete choice experiment  Journal Articles
• Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?  Journal Articles
• Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery  Journal Articles
• Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice  Journal Articles
• Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH  Journal Articles
• Evaluation of the sexual health in people living with hemophilia  Journal Articles
• Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU  Journal Articles
• Expression of Human Factor IX by Microencapsulated Recombinant Fibroblasts  Journal Articles
• Factor IX pharmacokinetics: differences between plasma‐derived and recombinant products and the clinical and economic implications: a meeting report  Conferences
• Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.  Journal Articles
• HIV Infection in a Defined Population of Swedish Haemophiliacs  Journal Articles
• Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics  Journal Articles
• Hemophilia B (Christmas disease) variants and carrier detection analyzed by DNA probes.  Journal Articles
• Hemophilia gene therapy: first, do no harm  Journal Articles
• Hepatitis E virus infection in hemophiliacs  Journal Articles
• Hepatitis, Epidemiology and Liver Function in Hemophiliacs in Sweden  Journal Articles
• High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice  Journal Articles
• Immune tolerance induction for a patient with factor IX inhibitors - a case report  Journal Articles
• Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B  Journal Articles
• Immunoglobulin levels in haemophiliacs at HIV seroconversion and during follow up  Journal Articles
• Inhibitor development in haemophilia according to concentrate  Journal Articles
• Inhibitor development in non-severe haemophilia across Europe  Journal Articles
• Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors  Journal Articles
• Joint WFH‐ISTH session: issues in clinical trial design  Journal Articles
• Joint Bleeding Tendencies in Adult Patients With Hemophilia: It’s Not All Pharmacokinetics  Journal Articles
• Limited Protective Effect of the CCR5Δ32/CCR5Δ32 Genotype on Human Immunodeficiency Virus Infection Incidence in a Cohort of Patients with Hemophilia and Selection for Genotypic X4 Virus  Journal Articles
• Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children  Journal Articles
• Low prevalence of inhibitor antibodies in the Canadian haemophilia population  Journal Articles
• Methodologies for data collection in congenital haemophilia with inhibitors (CHwI): critical assessment of the literature and lessons learned from recombinant factor VIIa  Journal Articles
• More on: are randomized clinical trials the only truth? Not always  Journal Articles
• Mortality and causes of death in Italian persons with haemophilia, 1990–2007  Journal Articles
• Mutation Analysis in F9 Gene of 17 Families with Haemophilia B from Iran  Conferences
• On‐demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome  Journal Articles
• Orthotopic liver transplantation in a patient with combined hemophilia A and B  Journal Articles
• Outcomes indicators and processes in transitional care in adolescents with haemophilia: A Delphi survey of Canadian haemophilia care providers  Journal Articles
• Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B  Journal Articles
• Persistent Delivery of Factor IX in Mice: Gene Therapy for Hemophilia Using Implantable Microcapsules  Journal Articles
• Pharmacokinetics of recombinant and plasma-derived factor IX products in pediatric patients with severe hemophilia B  Journal Articles
• Prevalence of hepatitis C virus infection among patients with inherited bleeding disorders in Newfoundland.  Journal Articles
• Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized  Journal Articles
• Propagating factor IX-producing hepatocytes for haemophilia B therapy  Journal Articles
• Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature  Journal Articles
• Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors  Journal Articles
• Redefining Disease? The Nosologic Implications of Molecular Genetic Knowledge  Journal Articles
• Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy.  Journal Articles
• Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: Results from the HERO qualitative study  Journal Articles
• Survey of the Canadian hemophilia population.  Journal Articles
• Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis  Journal Articles
• Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells  Journal Articles
• Sustained expression of coagulation factor IX by modified cord blood‐derived mesenchymal stromal cells  Journal Articles
• Switching patients in the age of long-acting recombinant products?  Journal Articles
• Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates  Journal Articles
• The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas.  Journal Articles
• The current state of adverse event reporting in hemophilia  Journal Articles
• The plasma concentration of activated protein C appears normal in patients with haemophilia  Journal Articles
• The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey  Journal Articles
• Treatment decision‐making among Canadian youth with severe haemophilia: a qualitative approach  Journal Articles
• Treatment of hemophilia B in mice with nonautologous somatic gene therapeutics  Journal Articles
• Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders  Journal Articles
• Validation of a composite score for clinical severity of hemophilia  Journal Articles
• What should men living with haemophilia need to know? The perspectives of Canadian men with haemophilia  Journal Articles
• [Centralized care is the basis of care programs for hemophilia patients].  Journal Articles
• [Cure of hemophilia is approaching. Gene therapy is the hope].  Journal Articles